Centers for Disease Control and Prevention (CDC) gave final approval for use of the Novavax COVID-19 vaccine.
Centers for Disease Control and Prevention (CDC) gave final approval for use of the Novavax COVID-19 vaccine in adults aged 18 and older, as a two-dose primary COVID-19 vaccine series with the two doses separated by three weeks. Novavax’s vaccine is protein-based like other familiar vaccines such as hepatitis B, HPV, pertussis and tetanus. Novavax may be preferable for some people who would rather receive a vaccine other than an mRNA-based vaccine. It may also be clinically recommended for people who can’t get either Pfizer or Moderna. Last week the federal government announced it secured 3.2 million doses of the Novavax vaccine but they are still finalizing details about when it will be widely available in Colorado. Learn more.